Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
Integration with Comprehensive Health Protocols For best results, therapy is often incorporated into a broader health and wellness plan, which may include lifestyle changes, dietary adjustments, and other complementary treatments
1 Introduction Cancer persists as the second leading cause of global mortality, with epidemiological projections estimating 19.97 million new cases and 9.74 million deaths in 2024 ( Nutraceuticals have emerged as compelling candidates in translational oncology, leveraging their dual capacity to potentiate anticancer effects while mitigating treatment-related toxicity ( 2 O 2 )-mediated responses, including adenosine triphosphate (ATP) depletion, iron-regulated epigenetic reprogramming, anti-apoptotic protein B cell lymphoma 2 (Bcl-2) inhibition, Bax (Bcl-2 associated X protein, a well-known pro-apoptotic mediator) activation, mitochondrial hyperpolarization induction, the cleavage of poly (ADP-ribose) polymerase (PARP, a known apoptotic indicator) and caspases, mainly caspases 3 and 7 as well as targeting hypoxia-inducible factor-1 ( HIF- ) ( The therapeutic application of VC in oncology has been plagued by persistent controversies, particularly regarding dose-response relationships and administration route efficacy
Chronic Conditions: Patients with conditions like sepsis or severe arrhythmias are closely monitored, as IV therapy may affect blood pressure and electrolyte levels
The first weekly dose is a low dose of 2.5 mg
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use this medication
Hamzawy et al
US$ 24.96
US$ 28.60
US$ 21.97
